Hong Kong
Akeso Inc. Receives Milestone Payment from Sichuan Kelun for PD-L1 Antibody Tagitanlimab After China’s Regulatory Approval
Akeso Inc. (9926.HK) announced that it had received payment from Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. ("Sichuan Kelun") for their coll...
January 23, 2025 | News
Ascletis Pharma Reports Promising Results for ASC30 Oral Tablet in Obesity Treatment
ASC30 oral tablet demonstrated dose-proportional pharmacokinetic (PK) properties and a long half-life (t1/2) up to 60 hours in the single ascending dose ...
January 22, 2025 | News
HKUST Researchers Develop World's Smallest Multifunctional Biomedical Robot for Precision Diagnosis and Treatment
Researchers from the School of Engineering of the Hong Kong University of Science and Technology (HKUST) have successfully developed the world's ...
January 21, 2025 | News
Guangzhou Fermion Partners with Simcere to Advance Clinical-Stage SSTR4 Agonist for Pain Management
Guangzhou Fermion Technology Co., Ltd. and Simcere Pharmaceutical Group Limited have announced a partnership to develop a clinical-stage pain treatment ass...
January 20, 2025 | News
Eyebright Medical Secures NMPA Approval for Loong Crystal PR, a Cutting-Edge Solution for Myopia Correction
Eyebright Medical Technology (Beijing) Co., Ltd. ("Eyebright Medical", the "Company", Stock Code: 688050.SH, together with its subsidiaries coll...
January 08, 2025 | News
HKSH Cancer Centre Hosts Sixth Symposium on Cancer Management, Celebrates One Year of Proton Therapy Milestones
HKSH Cancer Centre organised the sixth "HKSH Symposium on Advances in Cancer Management" ("The Symposium") which was held on 12 December 2024 at ...
January 03, 2025 | News
Sanofi Acquires Greater China Rights for Aficamten from CORXEL, Expanding HCM Treatment Reach
Cytokinetics, Incorporated announced that Sanofi will acquire exclusive rights to develop and commercialize aficamten from Corxel Pharmaceuticals (CORXEL...
December 20, 2024 | News
Hong Kong DoH Approves AGAMREE® for Duchenne Muscular Dystrophy Treatment
Department of Health (DoH) of Hong Kong approved AGAMREE® for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older...
December 20, 2024 | News
Everest Medicines’ VELSIPITY® Prescribed in Mainland China, Pioneering New Ulcerative Colitis Treatment under Hong Kong-Macau Connect
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing an...
December 18, 2024 | News
Everest Medicines Announces First Prescription of VELSIPITY® for Ulcerative Colitis in Macau, Marking a Key Milestone in Asia
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing an...
December 13, 2024 | News
Hong Kong’s Viva Biotech Expands Global Footprint with Strategic Boston Branch Launch
Viva Biotech Holdings Group ("Viva Biotech") announced the official establishment of its new branch in Boston, USA. As a global leader in drug re...
December 12, 2024 | News
Alamar Biosciences Expands to APAC with ARGO™ HT System Installation at HKCeND
Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce its commercial presence in th...
December 09, 2024 | News
Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine (PCV20) Approved for Pediatric Use in Hong Kong
Pfizer announced that the Hong Kong Department of Health (DoH) has approved its 20-valent Pneumococcal Conjugate Vaccine (PCV20) for active immunization in...
December 04, 2024 | News
Everest Medicines’ New Drug Application for VELSIPITY® (etrasimod) Accepted in Hong Kong for Ulcerative Colitis
Everest Medicines , a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeut...
December 03, 2024 | News
Most Read
- Why Cell Therapy Systems Are Going Automatic: A New Era of Manufacturing
- Pioneering Precision: Top 15 Clinical and Lab Diagnostic Companies to Watch in 2025
- 2025 Pharma and Medical Device Trends for Manufacturing Leaders
- 25 High-Value Drugs Losing Patent Protection in 2025: What It Means for Healthcare
- BioPharma Trends 2025: 25 Key Insights Shaping Asia Pacific's Future
- Driving Oncology Forward: 25 Companies Redefining Antibody-Drug Conjugates (ADCs) in 2025
- 25 Biopharma Leaders Shaping a Sustainable 2025: Innovation Meets Environmental Responsibility
- 25 Leading AI Companies to Watch in 2025: Transforming Drug Discovery and Precision Medicine
- Mr. Brendan O’Callaghan Discusses Sanofi’s Singapore Modulus Facility: Advancing Biopharma Manufacturing and Pandemic Preparedness
- Shaping the Future of PCV Care: Insights from Roche’s Stefan Scheidl on the SALWEEN Trial
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Shaping a Health Innovation Hub: Alessandro Falcone Reflects on JLABS Singapore’s Milestone Year and Future Goals
Bio Jobs
- Ravindra Rao Joins GOBI Technologies as Director of Life Sciences – APAC
- Amgen Announces $900 Million Expansion of Ohio Biomanufacturing Facility, Boosting Investment to Over $1.4 Billion
- Thermo Fisher Scientific Appoints Former CVS Health CEO Karen S. Lynch to Board of Directors
- Merck KGaA Reshapes Leadership for the Future with Key Executive Moves
- Aarian Health Appoints Thomas Keller as Business Director to Drive Innovation and Growth
- Top Management Shakeups of 2024: Redefining Pharma, Biopharma, and Biotech Leadership
News
